Sweden's Camurus Q4 revenue falls 16%, misses estimates

Camurus AB

12/02/2026 06:14

Overview

Sweden biopharmaceutical firm's Q4 revenue fell 16%, missing analyst expectations

Company's royalties increased 47%, driven by product uptake and new launches

Company launched Oczyesa in Germany and resubmitted Oclaiz application to US FDA

Outlook

Camurus forecasts 2026 revenues between SEK 2.6 bln and SEK 2.9 bln

Company expects 2026 operating result between SEK 0.9 bln and SEK 1.2 bln

Result Drivers

UK DISTRIBUTION CHANGE - Revenue impacted by a one-time inventory repurchase due to change in UK distribution model

ROYALTIES INCREASE - Royalties increased 47% due to product uptake and new launches

R&D ADVANCEMENTS - Resubmission of Oclaiz application to US FDA and positive trial results for CAM2056

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
SEK 464 mln
SEK 584.28 mln (5 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Camurus AB is SEK809.00, about 20.7% above its February 11 closing price of SEK670.00

The stock recently traded at 36 times the next 12-month earnings vs. a P/E of 25 three months ago

Press Release: ID:nWkr3l3bCv

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)